Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Pedro R. Lowenstein"'
Autor:
Maria B. Garcia-Fabiani, Santiago Haase, Andrea Comba, Stephen Carney, Brandon McClellan, Kaushik Banerjee, Mahmoud S. Alghamri, Faisal Syed, Padma Kadiyala, Felipe J. Nunez, Marianela Candolfi, Antonela Asad, Nazareno Gonzalez, Marisa E. Aikins, Anna Schwendeman, James J. Moon, Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
High grade gliomas are malignant brain tumors that arise in the central nervous system, in patients of all ages. Currently, the standard of care, entailing surgery and chemo radiation, exhibits a survival rate of 14-17 months. Thus, there is an urgen
Externí odkaz:
https://doaj.org/article/e49bee1aa5e941549a4fe571f50575c6
Autor:
Mahmoud S. Alghamri, Brandon L. McClellan, Carson S. Hartlage, Santiago Haase, Syed Mohd Faisal, Rohit Thalla, Ali Dabaja, Kaushik Banerjee, Stephen V. Carney, Anzar A. Mujeeb, Michael R. Olin, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Gliomas are one of the most lethal types of cancers accounting for ∼80% of all central nervous system (CNS) primary malignancies. Among gliomas, glioblastomas (GBM) are the most aggressive, characterized by a median patient survival of fewer than 1
Externí odkaz:
https://doaj.org/article/d0bcbb33bc1e4b30b99e75b5f849bf8c
Publikováno v:
Molecular & Cellular Oncology, Vol 8, Iss 2 (2021)
Glioblastoma is an aggressive brain tumor with poor prognosis. The brain is protected by the blood–brain barrier, which precludes transport of chemotherapeutics. We developed nanoparticles that achieve delivery of small-interfering RNA against Stat
Externí odkaz:
https://doaj.org/article/51820f4ffd744729aac7202e83fa3556
Autor:
Mahmoud S. Alghamri, Kaushik Banerjee, Anzar A. Mujeeb, Ava Mauser, Ayman Taher, Rohit Thalla, Brandon L. McClellan, Maria L. Varela, Svetlana M. Stamatovic, Gabriela Martinez-Revollar, Anuska V. Andjelkovic, Jason V. Gregory, Padma Kadiyala, Alexandra Calinescu, Jennifer A. Jiménez, April A. Apfelbaum, Elizabeth R. Lawlor, Stephen Carney, Andrea Comba, Syed Mohd Faisal, Marcus Barissi, Marta B. Edwards, Henry Appelman, Yilun Sun, Jingyao Gan, Rose Ackermann, Anna Schwendeman, Marianela Candolfi, Michael R. Olin, Joerg Lahann, Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
ACS Nano
Glioblastoma (GBM) is an aggressive primary brain cancer; with a 5-year survival of ~5%. Challenges that hamper GBM therapeutic efficacy include: (i) tumor heterogeneity, (ii) treatment resistance, (iii) immunosuppressive tumor microenvironment (TME)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b753af4faafaed24e5ea318bc7ec661b
https://europepmc.org/articles/PMC9649873/
https://europepmc.org/articles/PMC9649873/
Autor:
Santiago Haase, Jessica C. Gauss, Stephen Carney, Maria G. Castro, Felipe J Nunez, Sheeba Pawar, Ramya Ravindran, Maria B. Garcia-Fabiani, Marta Edwards, Fernando M. Nunez, Padma Kadiyala, Pedro R. Lowenstein, Flor M. Mendez
Publikováno v:
Clin Cancer Res
Purpose: Diffuse intrinsic pontine glioma (DIPG) bears a dismal prognosis. A genetically engineered brainstem glioma model harboring the recurrent DIPG mutation, Activin A receptor type I (ACVR1)-G328V (mACVR1), was developed for testing an immune-st
Autor:
Alexandra Calinescu, Rohit Thalla, Mahmoud S. Alghamri, Jennifer A. Jiménez, Maria Luisa Varela, Marta Edwards, Jason V. Gregory, Marcus Barissi, Padma Kadiyala, April A. Apfelbaum, Gabriela Martinez-Revollar, Pedro R. Lowenstein, Andrea Comba, Stephen Carney, Anzar A. Mujeeb, Maria G. Castro, Joerg Lahann, Svetlana M. Stamatovic, Ayman Taher, Brandon L. McClellan, Michael R. Olin, Syed M Faisal, Anuska Andjelkovic-Zochowska, Kaushik Banerjee, Elizabeth R Lawlor, Henry D. Appelman
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor, with poor prognosis. Major obstacles hampering effective therapeutic response in GBM are tumor heterogeneity, high infiltration of immunosuppressive myeloid cells, and the presence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30efcd31438b70159553640e479fe886
https://doi.org/10.1101/2021.08.27.457953
https://doi.org/10.1101/2021.08.27.457953
Autor:
Gabriel Núñez, Robert Doherty, Padma Kadiyala, Maria G. Castro, Diana Shah, Syed M Faisal, Daniel Zamler, Andrea Comba, Pedro R. Lowenstein, Gregory J. Baker, Mahmoud S. Alghamri
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Although pharmacological stimulation of TLRs has anti-tumor effects, it has not been determined whether endogenous stimulation of TLRs can lead to tumor rejection. Herein, we demonstrate the existence of an innate anti-glioma NK-mediated circuit init
Publikováno v:
Molecular & Cellular Oncology
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Glioblastoma is an aggressive brain tumor with poor prognosis. The brain is protected by the blood–brain barrier, which precludes transport of chemotherapeutics. We developed nanoparticles that achieve delivery of small-interfering RNA against Stat
Publikováno v:
Oncotarget
Diffuse intrinsic pontine glioma (DIPG) is a rare brainstem tumor which carries a dismal prognosis. To date. there are no effective treatments for DIPG. Transcriptomic studies have shown that DIPGs have a distinct profile compared to hemispheric high
Autor:
Kaushik Banerjee, Felipe J. Núñez, Santiago Haase, Brandon L. McClellan, Syed M. Faisal, Stephen V. Carney, Jin Yu, Mahmoud S. Alghamri, Antonela S. Asad, Alejandro J. Nicola Candia, Maria Luisa Varela, Marianela Candolfi, Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
Frontiers in Molecular Neuroscience
Frontiers in Molecular Neuroscience, Vol 14 (2021)
Frontiers in Molecular Neuroscience, Vol 14 (2021)
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and